IP Library › Granted Patent US 7,993,831

Granted Patent B2

US 7,993,831 · App. 11/855,792 · Granted Aug 9, 2011

Methods of normalization in microRNA detection assays

Assignee: Asuragen, Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,993,831
App. No.: 11/855,792
Granted: Aug 9, 2011
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This application describes methods of quantifying a target miRNA in a biological sample by measuring the amounts of a target miRNA and at least one reference oncomir in a reaction volume, and normalizing the amount of target miRNA to the amount of one or more reference oncomirs.

Claims (39)

1. A method of quantifying the amount of a target microRNA (miRNA) in a biological fluid or tissue sample, the method comprising:

(a) measuring the amount of the target miRNA in the sample in a reaction volume;

(b) measuring the amount of at least one endogenous reference oncomir in the reaction volume; and

2. The method of claim 1 , comprising measuring the amount of a first and a second endogenous reference oncomir in the biological fluid or tissue sample and normalizing the target miRNA levels to the first and second endogenous reference oncomirs.

3. The method of claim 1 , further comprising amplifying the target miRNA and the at least one endogenous reference oncomir in the reaction volume.

4. The method of claim 3 , wherein the amplification includes real-time polymerase chain reaction amplification.

5. The method of claim 1 , wherein the at least one endogenous reference oncomir is chosen from let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-100, miR-103, miR-106a, miR-107, miR-10a, miR-10b, miR-122, miR-125a, miR-125b, miR-126, miR-126*, miR-127-3p, miR-128a, miR-129, miR-133b, miR-135b, miR-137, miR-141, miR-143, miR-145, miR-146a, miR-146b, miR-148a, miR-149, miR-150, miR-155, miR-15a, miR-17-3p, miR-17-5p, miR-181a, miR-181b, miR-181c, miR-183, miR-184, miR-186, miR-187, miR-189, miR-18a, miR-190, miR-191, miR-192, miR-197, miR-199a, miR-199a*, miR-19a, miR-19b, miR-200a, miR-200a*, miR-200b, miR-200c, miR-202, miR-203, miR-205, miR-20a, miR-21, miR-210, miR-216, miR-218, miR-22, miR-221, miR-222, miR-223, miR-224, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-27a, miR-27b, miR-29a, miR-29b, miR-296-5p, miR-301, miR-302a, miR-302a*, miR-30a, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-30e-5p, miR-31, miR-320, miR-323, miR-324-5p, miR-326, miR-330, miR-331, miR-335, miR-346, miR-34a, miR-370, miR-372, miR-373, miR-373*, miR-497, miR-498, miR-503, miR-92, miR-93, miR-96, and miR-99a.

6. The method of claim 1 , wherein the at least one endogenous reference oncomir is chosen from hsa-miR-191, hsa-miR-93, hsa-miR-106a, hsa-miR-25, hsa-miR-17-5p, hsa-miR-103, hsa-miR-24, hsa-miR-99a, hsa-miR-320, hsa-miR-23a, hsa-miR-125a, hsa-miR-27a, hsa-miR-146a, and hsa-miR-195.

7. The method of claim 1 , wherein part (b) comprises measuring the amount of miR-191.

8. The method of claim 1 , wherein part (b) comprises measuring the amount of miR-103.

9. The method of claim 1 , wherein measuring the amount of at least one reference oncomir consists of measuring a first and a second endogenous reference oncomir.

10. The method of claim 9 , wherein the first and second endogenous reference oncomir are each chosen from hsa-miR-191, hsa-miR-93, hsa-miR-106a, hsa-miR-25, hsa-miR-17-5p, hsa-miR-16, hsa-let-7a, hsa-miR-103, hsa-miR-24, hsa-miR-99a, hsa-miR-320, hsa-miR-23a, hsa-miR-30d, hsa-miR-125a, hsa-miR-27a, hsa-miR-146a, hsa-miR-195, hsa-miR-143, and hsa-miR-221.

11. The method of claim 9 , wherein the first and second endogenous reference oncomirs are a pair chosen from hsa-miR-191 and hsa-miR-93, hsa-miR-25 and hsa-miR-191, hsa-let-7a and hsa-miR-103, and hsa-miR-17-5p and hsa-miR-24.

12. The method of claim 1 , wherein measuring the amount of at least one endogenous reference oncomir consists of measuring a endogenous reference oncomir chosen from hsa-miR-191, hsa-miR-93, hsa-miR-106a, hsa-miR-25, hsa-miR-17-5p, hsa-miR-103, hsa-miR-24, hsa-miR-99a, hsa-miR-320, hsa-miR-23a, hsa-miR-125a, hsa-miR-27a, hsa-miR-146a, and hsa-miR-195.

13. A method of normalizing the amount of a target miRNA in a biological fluid or tissue sample, comprising measuring the amount of the target miRNA and the amount of a first endogenous reference oncomir in the sample in a single reaction volume and normalizing the target miRNA measurement based on the amount of the reference oncomir in the sample.

14. The method of claim 13 , further comprising measuring the amount of a second endogenous reference oncomir in the biological fluid or tissue sample and normalizing the target miRNA level to the first and second reference oncomirs.

15. The method of claim 13 , further comprising amplifying the target miRNA and the first endogenous reference oncomir in the reaction volume.

16. The method of claim 14 , wherein the first and second endogenous reference oncomirs are chosen from hsa-miR-191, hsa-miR-93, hsa-miR-106a, hsa-miR-25, hsa-miR-17-5p, hsa-miR-16, hsa-let-7a, hsa-miR-103, hsa-miR-24, hsa-miR-99a, hsa-miR-320, hsa-miR-23a, hsa-miR-125a, hsa-miR-27a, hsa-miR-146a, and hsa-miR-195.

17. A method for quantifying the relative expression of a target miRNA in biological fluid or tissue samples, the method comprising:

(a) measuring the amount of the target miRNA sequence and a first endogenous reference oncomir sequence in a first biological sample in a first reaction volume;

(b) measuring the amount of the target miRNA sequence and the first reference oncomir endogenous sequence in a second biological sample in a second reaction volume; and

thereby quantifying the relative expression of the target miRNA.

18. The method of claim 17 , further comprising amplifying the target miRNA and the first endogenous reference oncomir in the first reaction volume and amplifying the target miRNA and the first endogenous reference oncomir in the second reaction volume.

19. A method of quantifying the amount of a target microRNA (miRNA) in a biological fluid or tissue sample, the method comprising:

(a) measuring the amount of the target miRNA in the sample;

(b) measuring the amount of one to three endogenous reference oncomirs chosen from let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-100, miR-103, miR-106a, miR-107, miR-10a, miR-10b, miR-122, miR-125a, miR-125b, miR-126, miR-126*, miR-127-3p, miR-128a, miR-129, miR-133b, miR-135b, miR-137, miR-141, miR-143, miR-145, miR-146a, miR-146b, miR-148a, miR-149, miR-150, miR-155, miR-15a, miR-17-3p, miR-17-5p, miR-181a, miR-181b, miR-181c, miR-183, miR-184, miR-186, miR-187, miR-189, miR-18a, miR-190, miR-191, miR-192, miR-195, miR-197, miR-199a, miR-199a*, miR-19a, miR-19b, miR-200a, miR-200a*, miR-200b, miR-200c, miR-202, miR-203, miR-205, miR-20a, miR-21, miR-210, miR-216, miR-218, miR-22, miR-221, miR-222, miR-223, miR-224, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-27a, miR-27b, miR-29a, miR-29b, miR-296-5p, miR-301, miR-302a, miR-302a*, miR-30a, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-30e-5p, miR-31, miR-320, miR-323, miR-324-5p, miR-326, miR-330, miR-331, miR-335, miR-346, miR-34a, miR-370, miR-372, miR-373, miR-373*, miR-497, miR-498, miR-503, miR-92, miR-93, miR-96, and miR-99a in the sample; and

20. The method of claim 19 , comprising measuring the amount of two or three endogenous reference oncomirs in the biological fluid or tissue sample and normalizing the target miRNA levels to the reference oncomirs.

21. The method of claim 19 , wherein the endogenous reference oncomir is chosen from hsa-miR-191, hsa-miR-93, hsa-miR-106a, hsa-miR-25, hsa-miR-17-5p, hsa-miR-103, hsa-miR-24, hsa-miR-99a, hsa-miR-320, hsa-miR-23a, hsa-miR-125a, hsa-miR-27a, hsa-miR-146a, and hsa-miR-195.

22. The method of claim 19 , wherein part (b) comprises measuring the amount of miR-191.

23. The method of claim 19 wherein part (b) comprises measuring the amount of miR-103.

24. A kit for quantifying the amount of a target miRNA in a biological fluid or tissue sample comprising:

(a) a first amplification primer set, wherein at least one primer comprises a sequence that is complementary to a portion of a target miRNA;

(b) a second amplification primer set, wherein at least one primer comprises a sequence that is complementary to a portion of an endogenous reference oncomir;

(d) a second probe comprising a sequence that is complementary to a portion of the endogenous reference oncomir;

wherein the first and second probes are distinguishably detectable.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2007

From: LATHAM, GARY J.; PELTIER, HEIDI J.

To: ASURAGEN, INC.

Reel/Frame 020113/0103 →

Continuity (1)

Related Publication 20090075258A1 · Mar 19, 2009